- Home
- ANAB vs DMC Comparison
ANAB vs DMC Comparison
Compare ANAB & DMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANAB | DMC |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2015 | 1999 |
Fundamental Metrics
Financial Performance| Metric | ANAB | DMC |
|---|---|---|
| Price | $57.29 | $31.39 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $71.67 | N/A |
| AVG Volume (30 Days) | ★ 374.8K | 337.5K |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.02 | N/A |
| EPS | N/A | ★ 0.65 |
| Revenue | $234,603,000.00 | ★ $4,322,300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $52.14 | N/A |
| P/E Ratio | ★ N/A | $48.52 |
| Revenue Growth | ★ 157.01 | 0.98 |
| 52 Week Low | $17.11 | $27.51 |
| 52 Week High | $73.30 | $32.50 |
Technical Indicators
Market Signals| Indicator | ANAB | DMC |
|---|---|---|
| Relative Strength Index (RSI) | 50.01 | 66.18 |
| Support Level | $53.46 | $27.82 |
| Resistance Level | $57.70 | $32.50 |
| Average True Range (ATR) | 2.36 | 0.73 |
| MACD | 0.18 | 0.07 |
| Stochastic Oscillator | 41.32 | 69.42 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About DMC Del Monte Corporation Ordinary Shares
Del Monte Corp is a producer, marketer, and distributor of fresh, packaged, value-added, and canned food products. Its products are sold in multiple countries and are marketed under the DEL MONTE brand and other brands.